ARL4A

Across TCGA pan-cancer cohorts, ARL4A RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of ARL4A’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where ARL4A RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ARL4A is over-expressed in tumor, although a few such as THCA and COAD show the opposite, repressed pattern.

KIRC, THCA, and LIHC are the cancer types where ARL4A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARL4A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	IV	+1.165	<.001	11	view →
THCA	Male	III,IV	−1.264	<.001	10	view →
LIHC	Male	II,III,IV	+1.320	<.001	7	view →
COAD	Female	All	−1.003	<.001	7	view →
BRCA	Female	All	−1.504	<.001	6	view →
KIRP	All	All	+0.450	.003	6	view →
UCEC	All	All	−0.876	.004	4	view →
CHOL	Male	All	+2.216	<.001	3	view →
BLCA	All	IV	−0.861	.004	2	view →
PRAD	All	All	−0.624	<.001	2	view →
LUSC	Female	II,III,IV	−0.652	.003	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

ARL4A–KIRC

Open the KIRC breakdown →